Log in

Relevant bibliographies by topics / MSIS – 29 – Multiple Sclerosis Impact Scale / Journal articles

To see the other types of publications on this topic, follow the link: MSIS – 29 – Multiple Sclerosis Impact Scale.

Journal articles on the topic 'MSIS – 29 – Multiple Sclerosis Impact Scale'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MSIS – 29 – Multiple Sclerosis Impact Scale.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Costelloe, L., K. O'Rourke, C. McGuigan, C. Walsh, N. Tubridy, and M. Hutchinson. "The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite." Multiple Sclerosis Journal 14, no. 2 (2007): 255–58. http://dx.doi.org/10.1177/1352458507081274.

Full text

Abstract:

Background To examine the longitudinal relationship between the patient-rated Multiple Sclerosis Impact Scale (MSIS-29) and the doctor-reported Multiple Sclerosis Functional Composite (MSFC). Methods Two-hundred and four MS patients at baseline and 150 patients one to three years later had MSFC and MSIS-29 assessments. Cross-sectional correlations between these measures and correlations of change in scores were examined. Minimally important change (MIC) in the MSFC was defined at either 0.5 or 0.32 SD from baseline. Effect sizes (ES) were calculated. Results Validity: The MSIS-29 physical corr

APA, Harvard, Vancouver, ISO, and other styles

2

Sonder, JM, LVAE Bosma, FAH van der Linden, DL Knol, CH Polman, and BMJ Uitdehaag. "Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales." Multiple Sclerosis Journal 18, no. 2 (2011): 196–201. http://dx.doi.org/10.1177/1352458511417827.

Full text

Abstract:

Background: Patient-reported outcome (PRO) scales are often used in multiple sclerosis (MS) research. Full understanding of items can be influenced by disease worsening, mood disturbances and cognitive problems of the MS patient. Earlier research with the Multiple Sclerosis Impact Scale (MSIS-29) showed that proxy respondents (i.e. partners of patients) can provide useful information. Objective: To determine agreement between patients and proxy respondents on different MS PRO scales. Methods: 139 Patients and partners completed the MSIS-29 (Physical and Psychological scale), Multiple Sclerosis

APA, Harvard, Vancouver, ISO, and other styles

3

Ayatollahi, P., S. Nafissi, MR Eshraghian, H. Kaviani, and A. Tarazi. "Impact of depression and disability on quality of life in Iranian patients with multiple sclerosis." Multiple Sclerosis Journal 13, no. 2 (2007): 275–77. http://dx.doi.org/10.1177/1352458506070960.

Full text

Abstract:

Multiple sclerosis (MS) can influence all aspects of a patient's health. This study determines the main factors affecting quality of life (QoL) in Iranian MS patients. QoL (Multiple Sclerosis Impact Scale; MSIS-29), disability (Expanded Disability Status Scale; EDSS) and depression (Beck Depression Inventory; BDI) were assessed in 106 MS patients. EDSS, clinical course and MS duration significantly correlated with physical MSIS-29. Depression highly correlated with both physical and psychological MSIS-29. Regression analyses showed that depression and EDSS predicted physical health. Psychologi

APA, Harvard, Vancouver, ISO, and other styles

4

Phillips, Glenn A., Kathleen W. Wyrwich, Shien Guo, et al. "Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening." Multiple Sclerosis Journal 20, no. 13 (2014): 1753–60. http://dx.doi.org/10.1177/1352458514530489.

Full text

Abstract:

Background: The 29-item Multiple Sclerosis Impact Scale (MSIS-29) was developed to examine the impact of multiple sclerosis (MS) on physical and psychological functioning from a patient’s perspective. Objective: To determine the responder definition (RD) of the MSIS-29 physical impact subscale (PHYS) in a group of patients with relapsing–remitting MS (RRMS) participating in a clinical trial. Methods: Data from the SELECT trial comparing daclizumab high-yield process with placebo in patients with RRMS were used. Physical function was evaluated in SELECT using three patient-reported outcomes mea

APA, Harvard, Vancouver, ISO, and other styles

5

Hoogervorst, E. LJ, J. NP Zwemmer, B. Jelles, C. H. Polman, and B. MJ Uitdehaag. "Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability." Multiple Sclerosis Journal 10, no. 5 (2004): 569–74. http://dx.doi.org/10.1191/1352458504ms1078oa.

Full text

Abstract:

Objective: To validate the newly developed Multiple Sclerosis Impact Scale (MSIS-29) in a large, well characterized, independent group of MS patients by investigating the relation between the MSIS-29 and the Guy’s Neurological Disability Scale (GNDS), the Expanded Disability Status Scale (EDSS) and the MS Functional Composite (MSFC). Methods: Two hundred MS patients were recruited at our outpatient department. At the same visit GNDS, EDSS, MSFC and MSIS-29 were assessed. Data obtained from GNDS, EDSS and MSFC assessment were compared to both physical and psychological impact scores of the MSIS

APA, Harvard, Vancouver, ISO, and other styles

6

Bacci, ED, KW Wyrwich, GA Phillips, T. Vollmer, and S. Guo. "Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing–remitting multiple sclerosis using classical and modern test theory." Multiple Sclerosis Journal - Experimental, Translational and Clinical 2 (January 2016): 205521731667323. http://dx.doi.org/10.1177/2055217316673235.

Full text

Abstract:

Background Investigations using classical test theory support the psychometric properties of the original version of the Multiple Sclerosis Impact Scale (MSIS-29v1), a disease-specific measure of multiple sclerosis (MS) impact (physical and psychological subscales). Later, assessments of the MSIS-29v1 in an MS community-based sample using Rasch analysis led to revisions of the instrument’s response options (MSIS-29v2). Objective The objective of this paper is to evaluate the psychometric properties of the MSIS-29v1 in a clinical trial cohort of relapsing–remitting MS patients (RRMS). Methods D

APA, Harvard, Vancouver, ISO, and other styles

7

Bosma, LVAE, JM Sonder, JJ Kragt, CH Polman, and BMJ Uitdehaag. "Detecting clinically-relevant changes in progressive multiple sclerosis." Multiple Sclerosis Journal 21, no. 2 (2014): 171–79. http://dx.doi.org/10.1177/1352458514540969.

Full text

Abstract:

Objective: To investigate which changes in different clinical outcome measures contribute most to increased disease impact, as reported by the patient, in progressive multiple sclerosis (MS). Methods: From a cohort of prospectively-followed MS patients, we selected progressive patients with two visits, 4–6 years apart. We assessed long-term changes on the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT) and Guy’s Neurological Disability Scale (GNDS). We defined the presence or absence of clinically meaningful change by using the Multiple Sclerosis Imp

APA, Harvard, Vancouver, ISO, and other styles

8

Moridi, Thomas, Leszek Stawiarz, Kyla A. McKay, et al. "Association between brain volume and disability over time in multiple sclerosis." Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, no. 4 (2022): 205521732211442. http://dx.doi.org/10.1177/20552173221144230.

Full text

Abstract:

Background Most previous multiple sclerosis (MS) brain atrophy studies using MS impact scale 29 (MSIS-29) or symbol digit modalities test (SDMT) have been cross-sectional with limited sets of clinical outcomes. Objectives To investigate which brain and lesion volume metrics show the strongest long-term associations with the expanded disability status scale (EDSS), SDMT, and MSIS-29, and whether MRI-clinical associations vary with age. Methods We acquired MRI and clinical data from a real-world Swedish MS cohort. FreeSurfer and SPM Lesion Segmentation Tool were used to obtain brain parenchymal,

APA, Harvard, Vancouver, ISO, and other styles

9

Kehoe, M., J. Saunders, P. Jakeman, and S. Coote. "Predictors of the physical impact of Multiple Sclerosis following community-based, exercise trial." Multiple Sclerosis Journal 21, no. 5 (2014): 590–98. http://dx.doi.org/10.1177/1352458514549395.

Full text

Abstract:

Background: Studies evaluating exercise interventions in people with multiple sclerosis (PwMS) demonstrate small to medium positive effects and large variability on a number of outcome measures. No study to date has tried to explain this variability. Objective: This paper presents a novel exploration of data examining the predictors of outcome for PwMS with minimal gait impairment following a randomised, controlled trial evaluating community-based exercise interventions ( N = 242). Methods: The primary variable was the physical component of the Multiple Sclerosis Impact Scale-29, version 2 (MS

APA, Harvard, Vancouver, ISO, and other styles

10

Gray, OM, GV McDonnell, and SA Hawkins. "Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study." Multiple Sclerosis Journal 15, no. 1 (2009): 75–80. http://dx.doi.org/10.1177/1352458508096872.

Full text

Abstract:

Objective To investigate the psychometric properties of the Multiple Sclerosis Impact Scale (MSIS-29) and to assess the relationship between the Kurtzke Expanded Disability Status Scale and the physical and psychological parts of this score. Methods A population-based study identified cases with definite multiple sclerosis (MS) in the north-east region of Ireland. They were examined and completed the MSIS-29. Cases were classified as mild (Expanded Disability Status Score (EDSS) 0–3.0), moderate (EDSS 3.5–5.5), or severe (6.0–9.5) MS. Results The 248 participants (82 male, 166 female) had a me

APA, Harvard, Vancouver, ISO, and other styles

11

Smedal, T., H. H. Johansen, K. M. Myhr, and L. I. Strand. "Psychometric properties of a Norwegian version of Multiple Sclerosis Impact Scale (MSIS-29)." Acta Neurologica Scandinavica 122, no. 4 (2009): 244–51. http://dx.doi.org/10.1111/j.1600-0404.2009.01298.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Hobart, J. "The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure." Brain 124, no. 5 (2001): 962–73. http://dx.doi.org/10.1093/brain/124.5.962.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Riazi, A. "Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples." Journal of Neurology, Neurosurgery & Psychiatry 73, no. 6 (2002): 701–4. http://dx.doi.org/10.1136/jnnp.73.6.701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

van der Linden, F. A. H. "Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use." Journal of Neurology, Neurosurgery & Psychiatry 76, no. 12 (2005): 1677–81. http://dx.doi.org/10.1136/jnnp.2005.065227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Wray, Sibyl, Francois Jacques, Tamara A. Miller, et al. "Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study." Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, no. 4 (2022): 205521732211358. http://dx.doi.org/10.1177/20552173221135888.

Full text

Abstract:

Background Patient-reported outcomes are increasingly used in the management of patients with multiple sclerosis to understand the patient's perspective of disease and treatment. These measures provide insights into important factors including treatment satisfaction, physical and psychological function, and quality of life. Objective To present results from the real-world PRO-ACT study in patients with multiple sclerosis who switched to alemtuzumab from another disease-modifying therapy. Methods This 24-month, prospective, multicenter, observational study had a primary endpoint of change in ov

APA, Harvard, Vancouver, ISO, and other styles

16

Sonder, Judith M., Lisanne J. Balk, Libertje VAE Bosma, Chris H. Polman, and Bernard MJ Uitdehaag. "Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales." Multiple Sclerosis Journal 20, no. 12 (2014): 1616–23. http://dx.doi.org/10.1177/1352458514529173.

Full text

Abstract:

Background: Patient-reported outcome scales (PROs) are useful in monitoring changes in multiple sclerosis (MS) over time. Although these scales are reliable and valid measures in longitudinal studies in MS patients, it is unknown what the impact is when obtaining longitudinal data from proxies. Objective: The objective of this paper is to compare longitudinal changes in patient and proxy responses on PROs assessing physical impact of MS and walking ability. Methods: In a prospective observational study, data on the Multiple Sclerosis Impact Scale (MSIS-29 physical) and Multiple Sclerosis Walki

APA, Harvard, Vancouver, ISO, and other styles

17

Jorge, Francielle Fontana, Alessandro Finkelsztejn, and Luciano Palmeiro Rodrigues. "Motor symptoms and the quality of life of relapsing-remitting multiple sclerosis patients in a specialized center in South of Brazil." Arquivos de Neuro-Psiquiatria 79, no. 10 (2021): 895–99. http://dx.doi.org/10.1590/0004-282x-anp-2020-0315.

Full text

Abstract:

Abstract Background: Spasticity, fatigue, muscle weakness and changes in gait are some of the main motor symptoms of Multiple Sclerosis (MS). These changes can interfere with the patients’ quality of life. Objective: To characterize the motor and quality of life symptoms in patients with relapsing-remitting Multiple Sclerosis at a specialized center. Methods: Fifty five patients at the Neuroimmunology Outpatient Clinic of the Hospital de Clínicas de Porto Alegre were evaluated for fatigue (Fatigue Severity Scale — FSS), walking ability (Functional Ambulation Categories — FAC), impact of MS on

APA, Harvard, Vancouver, ISO, and other styles

18

Osmani, D., K. Rajagopalan, and J. Hobart. "PND33 LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES." Value in Health 12, no. 7 (2009): A371. http://dx.doi.org/10.1016/s1098-3015(10)74827-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

O'Connell, K., M. Duggan, L. Buckley, M. Hutchinson, N. Tubridy, and C. McGuigan. "Longitudinal assessment of the multiple sclerosis impact scale (MSIS-29) amongst A treated relapsing remitting multiple sclerosis cohort." Journal of the Neurological Sciences 333 (October 2013): e374. http://dx.doi.org/10.1016/j.jns.2013.07.1364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lopes, Josiane, Damacio Ramón Kaimen Maciel, and Tiemi Matsuo. "Adaptação Transcultural e Validação da Escala de Impacto de Esclerose Múltipla." Revista Neurociências 19, no. 3 (2001): 433–40. http://dx.doi.org/10.34024/rnc.2011.v19.8349.

Full text

Abstract:

Introdução. A maioria dos instrumentos que avaliam a Qualidade de Vida (QV) de indivíduos com Esclerose Múltipla (EM) apresenta falhas psicométricas. A escala “Multiple Sclerosis Impact Scale (MSIS29)” é o instrumento mais adequado para avaliar o impacto da EM na saúde com abordagem funcional da QV. Objetivo. Realizar a adaptação transcultural e validação do instrumento MSIS-29 para a língua portuguesa (Brasil). Método. O MSIS-29 foi traduzido para o português, retrovertido para o inglês e analisadas as versões com aplicação em dois grupos de 15 indivíduos com EM até obtenção da versão final (

APA, Harvard, Vancouver, ISO, and other styles

21

Feys, Peter, Lousin Moumdjian, Florian Van Halewyck, et al. "Effects of an individual 12-week community-located “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis." Multiple Sclerosis Journal 25, no. 1 (2017): 92–103. http://dx.doi.org/10.1177/1352458517740211.

Full text

Abstract:

Background: Exercise therapy studies in persons with multiple sclerosis (pwMS) primarily focused on motor outcomes in mid disease stage, while cognitive function and neural correlates were only limitedly addressed. Objectives: This pragmatic randomized controlled study investigated the effects of a remotely supervised community-located “start-to-run” program on physical and cognitive function, fatigue, quality of life, brain volume, and connectivity. Method: In all, 42 pwMS were randomized to either experimental (EXP) or waiting list control (WLC) group. The EXP group received individualized t

APA, Harvard, Vancouver, ISO, and other styles

22

Adlard, NE, R. Rendas-Baum, JB Bjorner, K. Rychlec, V. Khurana, and J. Medin. "PRM197 - RESPONDER DEFINITION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS)-29 V2 AMONG PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS." Value in Health 21 (October 2018): S390. http://dx.doi.org/10.1016/j.jval.2018.09.2315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

He, Anna, Ali Manouchehrinia, Anna Glaser, et al. "Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context." JAMA Network Open 6, no. 9 (2023): e2334675. http://dx.doi.org/10.1001/jamanetworkopen.2023.34675.

Full text

Abstract:

ImportanceMultiple sclerosis (MS) severity may be informed by premorbid sociodemographic factors.ObjectiveTo determine whether premorbid education, income, and marital status are associated with future MS disability and symptom severity, independent of treatment, in a universal health care context.Design, Setting, and ParticipantsThis nationwide observational cohort study examined data from the Swedish MS Registry linked to national population registries from 2000 to 2020. Participants included people with MS onset from 2005 to 2015 and of working age (aged 23 to 59 years) 1 year and 5 years p

APA, Harvard, Vancouver, ISO, and other styles

24

Pavan, Karina, Bruna Eriko Matsuda Marangoni, Sergio Lianza, and Charles Peter Tilbery. "Padronização da Msis-29 Para um Centro de Referência em Esclerose Múltipla." Revista Neurociências 21, no. 2 (2013): 237–46. http://dx.doi.org/10.34024/rnc.2013.v21.8185.

Full text

Abstract:

Todas as ciências da saúde vêm reforçando a prática clínica baseada em evidências e mostra a importância da utilização de instrumentos validados. Multiple Sclerosis Impact Scale (MSIS-29) é instrumento de medida para avaliação do impacto físico e psicológico da Esclerose Múltipla (EM) na qualidade de vida. Objetivo. Padronizar as propriedades psicométricas da MSIS-29 para pacientes com EM do centro de referência, Centro de Atendimento e Tratamento da EM (CATEM). Método. Realizado estudo prospectivo com 100 indivíduos, 75% do sexo feminino, média de idade de 39,21±10,32 anos. As etapas do proc

APA, Harvard, Vancouver, ISO, and other styles

25

Dr., S. S. Subramanian*. "TEN YEARS FOLLOW UP OF MULTIPLE SCLEROSIS WITH PHYSIOTHERAPY – EVIDENCE BASED STUDY." Indian Journal of Medical Research and Pharmaceutical Sciences 4, no. 6 (2017): 72–77. https://doi.org/10.5281/zenodo.815712.

Full text

Abstract:

Multiple sclerosis, a progressive neurological degenerative disease, where physical, psychological and social aspects of rehabilitation is required on long term, with periodical evaluation and physiotherapy. This original study with 10 years follow up on a subject with multiple sclerosis highlights the clinical course and high lighten the impact of physiotherapy with evidence. Though the results of this study was negative with multiple sclerosis impact scale 29 increasing, along with expanded disability status doubling, physiotherapy has its domain in preventing, maintaining and provide better

APA, Harvard, Vancouver, ISO, and other styles

26

Dymecka, Joanna, and Mariola Bidzan. "Biomedical Variables and Adaptation to Disease and Health-Related Quality of Life in Polish Patients with MS." International Journal of Environmental Research and Public Health 15, no. 12 (2018): 2678. http://dx.doi.org/10.3390/ijerph15122678.

Full text

Abstract:

The aim of this research was to assess the level of adaptation to multiple sclerosis (Sclerosis multiplex; MS) and health-related quality of life (HRQoL) of the study population as well as to determine the relationship between biomedical factors related to the course of multiple sclerosis, adaptation to the disease, and HRQoL. Analysis of medical records, clinical and psychological interviews, the Extended Disability Status Scale (EDSS), Guy’s Neurological Disability Scale (GNDS), the Acceptance of Illness Scale (AIS), and the Multiple Sclerosis Impact Scale 29 (MSIS-29) were collected from 13

APA, Harvard, Vancouver, ISO, and other styles

27

Bosma, LVAE, JJ Kragt, CH Polman, and BMJ Uitdehaag. "Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS." Multiple Sclerosis Journal 19, no. 3 (2012): 326–33. http://dx.doi.org/10.1177/1352458512454346.

Full text

Abstract:

Objective: To study the relationships between 1–2 year changes in well-known physician-rated measurements (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT)) and the long-term (≥ 5 years) outcome in patient-reported outcome (PRO) measures (Multiple Sclerosis Impact Scale (MSIS-29), Multiple Sclerosis Walking Scale (MSWS-12)) that reflect the patient-perceived impact of disease, in progressive MS. Methods: We selected all progressive patients having at least two complete visits within 1-2 years, from a larger cohort of prospectively-followed MS patients

APA, Harvard, Vancouver, ISO, and other styles

28

Garrett, Maria, Neasa Hogan, Aidan Larkin, Jean Saunders, Philip Jakeman, and Susan Coote. "Exercise in the community for people with multiple sclerosis — a follow-up of people with minimal gait impairment." Multiple Sclerosis Journal 19, no. 6 (2012): 790–98. http://dx.doi.org/10.1177/1352458512461390.

Full text

Abstract:

Background: Although there are many studies evaluating exercise interventions, few studies have evaluated the effect at follow-up. Objectives: This paper presents follow-up data for participants who completed the exercise interventions in a large randomised controlled trial. Methods: One hundred twenty-one people with multiple sclerosis (MS) with minimal gait impairment who completed 10 weeks of community-based exercise interventions were evaluated by a blinded assessor 12 weeks after the intervention. The primary outcome measure was the Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29,v2

APA, Harvard, Vancouver, ISO, and other styles

29

Garrett, M., N. Hogan, A. Larkin, J. Saunders, P. Jakeman, and S. Coote. "Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial." Multiple Sclerosis Journal 19, no. 6 (2012): 782–89. http://dx.doi.org/10.1177/1352458512461966.

Full text

Abstract:

Background: While there is an increasing body of evidence supporting the efficacy of exercise in people with multiple sclerosis (MS), additional information on the effectiveness of combining aerobic and resistance training, and yoga is required. Objectives: This study evaluated the effectiveness of community exercise interventions for people with MS having minimal gait impairment. Methods: A multi-centred, block-randomised, assessor-blinded, controlled trial was conducted. Participants were randomised in groups of eight to physiotherapist (PT)-led exercise ( n = 80), yoga ( n = 77), fitness in

APA, Harvard, Vancouver, ISO, and other styles

30

Guo, S., I. Proskorovsky, and G. A. Phillips. "PND55 Multiple Sclerosis Impact Scale (MSIS-29): Its Validity and Responsiveness in Clinical Trial-Based Subjects." Value in Health 15, no. 7 (2012): A555. http://dx.doi.org/10.1016/j.jval.2012.08.1979.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cohan, Stanley, Ludwig Kappos, Gavin Giovannoni, et al. "Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE." Multiple Sclerosis Journal 24, no. 14 (2017): 1883–91. http://dx.doi.org/10.1177/1352458517735190.

Full text

Abstract:

Background: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. Objective: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE. Methods: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients

APA, Harvard, Vancouver, ISO, and other styles

32

Cleanthous, Sophie, Stefan Cano, Elizabeth Kinter, et al. "Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT)." Multiple Sclerosis Journal – Experimental, Translational and Clinical 3, no. 3 (2017): 205521731772591. http://dx.doi.org/10.1177/2055217317725917.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hobart, J. C. "How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales." Journal of Neurology, Neurosurgery & Psychiatry 76, no. 11 (2005): 1539–43. http://dx.doi.org/10.1136/jnnp.2005.064584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Rakusa, Martin, Jeremy Chataway, and Todd A. Hardy. "The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids." Pharmaceuticals 16, no. 9 (2023): 1244. http://dx.doi.org/10.3390/ph16091244.

Full text

Abstract:

Background: We assessed the prevalence and risks associated with pain during and after a multiple sclerosis (MS) relapse, and the impact of pain on quality of life (QoL), in MS patients. Methods: 117 patients suffering an acute MS relapse were evaluated with clinician- and patient-reported outcomes, including the expanded disability status scale (EDSS), Multiple Sclerosis Impact Scale (MSIS-29), and MS Walking scale-12 (MSWS-12). Relapse-related pain was assessed via the short-form 36 (SF-36) questionnaire upon first visit (relapse onset) and at 6 weeks after treatment with intravenous methylp

APA, Harvard, Vancouver, ISO, and other styles

35

Downing, Abbey, David Van Ryn, Anne Fecko, et al. "Effect of a 2-Week Trial of Functional Electrical Stimulation on Gait Function and Quality of Life in People with Multiple Sclerosis." International Journal of MS Care 16, no. 3 (2014): 146–52. http://dx.doi.org/10.7224/1537-2073.2013-032.

Full text

Abstract:

Background: Footdrop is a common gait deviation in people with multiple sclerosis (MS) leading to impaired gait and balance as well as decreased functional mobility. Functional electrical stimulation (FES) provides an alternative to the current standard of care for footdrop, an ankle-foot orthosis (AFO). FES stimulates the peroneal nerve and activates the dorsiflexor muscles, producing an active toe clearance and a more normal gait. This study was undertaken to determine the effects of a 2-week FES Home Assessment Program on gait speed, perceived walking ability, and quality of life (QOL) amon

APA, Harvard, Vancouver, ISO, and other styles

36

Kragt, JJ, JM Nielsen, FAH van der Linden, CH Polman, and BMJ Uitdehaag. "Disease progression in multiple sclerosis: combining physicians’ and patients’ perspectives?" Multiple Sclerosis Journal 17, no. 2 (2010): 234–40. http://dx.doi.org/10.1177/1352458510385505.

Full text

Abstract:

Background: To assess disease progression in multiple sclerosis (MS) several outcome measures are available. The interrelation of changes on different scales has not been studied extensively and the concept of combining scales has only recently been introduced in MS. Objective: To explore combining different clinical outcome measures in the evaluation of disease progression in MS. Methods: In 553 patients we studied the presence of relevant changes according to standard definitions on the Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW) and the Mul

APA, Harvard, Vancouver, ISO, and other styles

37

Hämäläinen, Päivi, Matias Viitala, Hanna Kuusisto, Juhani Ruutiainen, and Merja Soilu-Hänninen. "MyMS: An Interface for Patient-Reported Outcomes for Finnish Individuals With Multiple Sclerosis." International Journal of MS Care 26, Q4 (2024): 273–80. http://dx.doi.org/10.7224/1537-2073.2023-082.

Full text

Abstract:

ABSTRACT BACKGROUND: Patient-generated data are a cornerstone of individualized multiple sclerosis (MS) treatment. MyMS, an interface for patient-reported outcomes (PROs) was developed by the Finnish MS Register to enable systematic collection of PROs. METHODS: MyMS collects data on demographics, lifestyle factors, disease-related factors, and validated questionnaires, including the Quality of Life Questionnaire (15D), the Multiple Sclerosis Impact Scale (MSIS-29), and the Fatigue Severity Scale (FSS). At the end of 2020, the patient-reported Expanded Disability Status Scale (PREDSS), the Euro

APA, Harvard, Vancouver, ISO, and other styles

38

Rodgers, Jeff, Rod Middleton, James Witts, Elaine Craig, Katie Tuite-Dalton, and Richard Nicholas. "149 Down but not out repurposing depression treatments for multiple sclerosis with the UK MS register." Journal of Neurology, Neurosurgery & Psychiatry 93, no. 9 (2022): e2.105. http://dx.doi.org/10.1136/jnnp-2022-abn2.193.

Full text

Abstract:

IntroductionRepurposing treatments in multiple sclerosis (MS) has resulted in several candidates that are currently in phase 2 and 3 trials but to test candidate therapies requires a prolonged and costly study. Real world data offers the opportunity to assess in non-randomised data the potential of a range of commonly used therapies. The UK MS register is a UK-wide real-world dataset of 20,000 subjects where regular MS outcomes are collected. Using this dataset, we have recently shown the benefits of disease modifying therapies, and smoking cessation in MS. We aimed to determine if such a reso

APA, Harvard, Vancouver, ISO, and other styles

39

Flachenecker, Peter, Anna Karoline Bures, Angeli Gawlik, et al. "Efficacy of an Internet-Based Program to Promote Physical Activity and Exercise after Inpatient Rehabilitation in Persons with Multiple Sclerosis: A Randomized, Single-Blind, Controlled Study." International Journal of Environmental Research and Public Health 17, no. 12 (2020): 4544. http://dx.doi.org/10.3390/ijerph17124544.

Full text

Abstract:

Background: Multimodal rehabilitation improves fatigue and mobility in persons with multiple sclerosis (PwMS). Effects are transient and may be conserved by internet-based physical activity promotion programs. Objective: Evaluate the effects of internet-based physical activity and exercise promotion on fatigue, quality of life, and gait in PwMS after inpatient rehabilitation. Methods: PwMS (Expanded Disability Status Scale (EDSS) ≤ 6.0, fatigue: Würzburg Fatigue Inventory for Multiple Sclerosis (WEIMuS) ≥ 32) were randomized into an intervention group (IG) or a control group (CG). After rehabi

APA, Harvard, Vancouver, ISO, and other styles

40

McKay, Kyla A., Olivia Ernstsson, Ali Manouchehrinia, Tomas Olsson, and Jan Hillert. "Determinants of quality of life in pediatric- and adult-onset multiple sclerosis." Neurology 94, no. 9 (2019): e932-e941. http://dx.doi.org/10.1212/wnl.0000000000008667.

Full text

Abstract:

ObjectiveTo evaluate quality of life (QoL), measured by the EQ-5D, in adults with pediatric-onset multiple sclerosis (POMS) or adult-onset multiple sclerosis (AOMS) and explore determinants of QoL in both groups.MethodsData were collected from the nationwide Swedish multiple sclerosis (MS) registry. Demographic characteristics, EQ-5D-3 level, Multiple Sclerosis Impact Scale (MSIS-29) score, Expanded Disability Status Scale (EDSS) score, Symbol Digit Modalities Test score, relapses, and disease-modifying therapy (DMT) exposure were collected on an approximately annual basis (2011–2019). Patient

APA, Harvard, Vancouver, ISO, and other styles

41

Gann, Elliot J., Mark M. Mañago, Diane D. Allen, Elie Celnikier, and Valerie J. Block. "Feasibility of Telerehabilitation-Monitored Functional Electrical Stimulation on Walking and Quality of Life in People With Multiple Sclerosis: A Case Series." International Journal of MS Care 26, Q3 (2024): 214–23. http://dx.doi.org/10.7224/1537-2073.2023-081.

Full text

Abstract:

ABSTRACT BACKGROUND: Foot drop in people with multiple sclerosis (MS) commonly leads to decreased mobility and quality of life (QOL). Functional electrical stimulation (FES) of the peroneal nerve can improve the gait of people with foot drop, yet various barriers restrict widespread use. The purpose of this case series was to examine the feasibility of a telerehabilitation-monitored FES device and report changes in functional mobility and QOL in people with moderate MS-related disability. METHODS: FES use was progressed over 8 weeks via 3 telerehabilitation sessions. Feasibility of telerehabil

APA, Harvard, Vancouver, ISO, and other styles

42

Malone, Tiffany, John A. Schafer, Lacey Sayre, and Brian Hutchinson. "Outcomes of a Day Wellness Program for People With Multiple Sclerosis Before and During the COVID-19 Pandemic." International Journal of MS Care 26, Q3 (2024): 233–38. http://dx.doi.org/10.7224/1537-2073.2023-018.

Full text

Abstract:

ABSTRACT BACKGROUND: The John A. Schafer, MD Multiple Sclerosis Achievement Center (MSAC) conducts wellness programs that include exercise, cognitive stimulation, education, emotional support, and socialization for people with multiple sclerosis and their care partners. Patient-reported outcomes (PROs) are collected annually. Four-year outcomes encompass the COVID-19 pandemic when some of these programs were offered virtually. METHODS: Beginning in 2017, baseline data were collected for 110 MSAC day wellness program participants through PRO measures. Of those 110, 52 completed PROs annually th

APA, Harvard, Vancouver, ISO, and other styles

43

Boesen, Finn, Michael Nørgaard, Philipp Trénel, et al. "Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial – The Danish MS Hospitals Rehabilitation Study." Multiple Sclerosis Journal 24, no. 3 (2017): 340–49. http://dx.doi.org/10.1177/1352458517735188.

Full text

Abstract:

Background: There is insufficient evidence to support the effectiveness of multidisciplinary rehabilitation on the health-related quality of life (HRQoL) of MS patients. Objectives: To evaluate the longer term effectiveness of inpatient multidisciplinary rehabilitation on the HRQoL of MS patients. Methods: The study was a two-hospital, pragmatic, randomized controlled trial with a 6-month follow-up. Patients aged 18–65 years with MS and Expanded Disability Status Scale scores ≤7.5 were randomly assigned (1:1) to 4 weeks of inpatient multidisciplinary rehabilitation (20 days of scheduled rehabi

APA, Harvard, Vancouver, ISO, and other styles

44

Riazi, A., A. J. Thompson, and J. C. Hobart. "Self-efficacy predicts self-reported health status in multiple sclerosis." Multiple Sclerosis Journal 10, no. 1 (2004): 61–66. http://dx.doi.org/10.1191/1352458504ms986oa.

Full text

Abstract:

Self-efficacy is a belief that one can competently cope with a challenging situation. If self-efficacy is a strong predicto r of health status in multiple sclerosis (MS), it may be an important area to target in clinical practice, as such beliefs may be modifiable. The aim of this study was to examine the predictive value of self-efficacy on self-reported health status in MS. Eighty-nine people with MS completed the Multiple Sclerosis Self-efficacy Scale (MSSE function and control scales), the Multiple Sclerosis Impact Scale (MSIS-29), and the Multiple Sclerosis Walking Scale (MSWS-12) at two

APA, Harvard, Vancouver, ISO, and other styles

45

Grus, Cyril. "Monitoring the relationship between overactive bladder and mobility disorders in women with multiple sclerosis." Česká gynekologie 88, no. 5 (2023): 353–58. http://dx.doi.org/10.48095/cccg2023353.

Full text

Abstract:

Summary: Background: Currently, there is a lack of studies monitoring the relationship between lower urinary tract symptoms and mobility disorders in women with multiple sclerosis. The aim of this study was to monitor the relationship between overactive bladder and mobility impairments in women with multiple sclerosis. Methods: A number of 106 female patients with multiple sclerosis (MS) with relapsing-remitting (RR) form, disability stage: EDSS ≤ 6.5, from the specialized outpatient clinic of the Department of Neurology, Faculty of Medicine, University of Medical Sciences in Košice. Urinary l

APA, Harvard, Vancouver, ISO, and other styles

46

Hirst, Claire L., Gillian Ingram, Trevor P. Pickersgill, and Neil P. Robertson. "Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome." Multiple Sclerosis Journal 18, no. 8 (2012): 1152–58. http://dx.doi.org/10.1177/1352458511433919.

Full text

Abstract:

Background: Relapse is a characteristic clinical feature of multiple sclerosis (MS) and is commonly employed as a measure of efficacy following therapeutic intervention. However, less is known about the temporal evolution of subsequent disability or factors predicting recovery. Objectives: The objective of this study was to assess the pattern of recovery following relapse and identify factors which predict recovery and residual disability following relapse. Methods: A total of 226 relapses were studied prospectively in a cohort of 144 patients with standardised clinical assessments of physical

APA, Harvard, Vancouver, ISO, and other styles

47

Guo, Jie, Tomas Olsson, Jan Hillert, Lars Alfredsson, and Anna Karin Hedström. "Education, Lifestyle Risk Factors, and Treatment Choices and Multiple Sclerosis Progression." JAMA Network Open 8, no. 7 (2025): e2520142. https://doi.org/10.1001/jamanetworkopen.2025.20142.

Full text

Abstract:

ImportanceThe implications of socioeconomic factors, including educational level, for multiple sclerosis (MS) progression remain unclear. Understanding whether educational level directly affects MS outcomes or is confounded by lifestyle risk factors and treatment choices could inform personalized care strategies.ObjectiveTo investigate the association between educational level and outcomes related to MS, including worsening of disability, cognition, and health-related quality of life, after adjusting for potential confounding factors or mediation by lifestyle factors and treatment.Design, Sett

APA, Harvard, Vancouver, ISO, and other styles

48

Costelloe, L., K. O'Rourke, H. Kearney, et al. "The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)." Journal of Neurology, Neurosurgery & Psychiatry 78, no. 8 (2007): 841–44. http://dx.doi.org/10.1136/jnnp.2006.105759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Paul, Lorna, Susan Coote, Jean Crosbie, et al. "Core outcome measures for exercise studies in people with multiple sclerosis: recommendations from a multidisciplinary consensus meeting." Multiple Sclerosis Journal 20, no. 12 (2014): 1641–50. http://dx.doi.org/10.1177/1352458514526944.

Full text

Abstract:

Evidence shows that exercise is beneficial for people with multiple sclerosis (MS); however, statistical pooling of data is difficult because of the diversity of outcome measures used. The objective of this review is to report the recommendations of an International Consensus Meeting for a core set of outcome measures for use in exercise studies in MS. From the 100 categories of the International Classification of Function Core Sets for MS, 57 categories were considered as likely/potentially likely to be affected by exercise and were clustered into seven core groups. Outcome measures to addres

APA, Harvard, Vancouver, ISO, and other styles

50

Metaxouli, Konstantina, Chrysoula Tsiou, Eleni Dokoutsidou, and Nikoletta Margari. "Nutritional Intervention in Patients with Multiple Sclerosis, Correlation with Quality of Life and Disability—A Prospective and Quasi-Experimental Study." NeuroSci 6, no. 1 (2025): 4. https://doi.org/10.3390/neurosci6010004.

Full text

Abstract:

Multiple sclerosis (MS) is a multifactorial disease, with diet and lifestyle playing an important role in its development. The Mediterranean diet has been considered to be particularly beneficial for MS patients. The aim of the present study was to investigate the relationship between diet and MS, as well as evaluate the effect of the Mediterranean diet on patients’ quality of life and level of disability. The six-month study included 130 patients, divided into a control and intervention group. Data collection instruments were used for the collection of demographic and medical characteristics

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!